MYGN vs TRIB
Myriad Genetics, Inc. and Trinity Biotech PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MYGN | TRIB |
|---|---|---|
| Revenue | $824.5M | $61.6M |
| Net income | $-365.9M | $-31.8M |
| Gross margin | 69.9% | 34.8% |
| Net margin | −44.4% | −51.6% |
| Return on equity | −68.5% | — |
| Diluted EPS | −$3.95 | — |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-151.6M | $-4.6M |
| Equity | $368.0M | — |
| Net debt / equity | −0.08× | — |
| Current ratio | 2.49× | 1.28× |
| Revenue CAGR 5y | 8.2% | −7.4% |
| Profit CAGR 5y | — | — |
MYGN bills 13.4× the revenue of TRIB, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | MYGN | TRIB |
|---|---|---|
| FY2024 | $837.6M | $61.6M |
| FY2023 | $753.2M | $56.8M |
| FY2022 | $678.4M | $62.5M |
| FY2021 | $690.6M | $81.1M |
| FY2020 | $557.1M | $102.0M |
| FY2019 | $638.6M | $90.4M |
| FY2018 | $851.1M | $97.0M |
| FY2017 | $743.7M | $99.1M |
| FY2016 | $728.7M | $99.6M |
| FY2015 | $740.5M | $100.2M |
Net income by year
Bottom line
| Fiscal year | MYGN | TRIB |
|---|---|---|
| FY2024 | $-127.3M | $-31.8M |
| FY2023 | $-263.3M | $-24.0M |
| FY2022 | $-112.0M | $-41.0M |
| FY2021 | $-27.2M | $875,000 |
| FY2020 | $-223.6M | $-6.4M |
| FY2019 | $-199.5M | $-28.9M |
| FY2018 | $4.6M | $-22.1M |
| FY2017 | $133.3M | $-40.3M |
| FY2016 | $17.4M | $-100.6M |
| FY2015 | $117.2M | $21.8M |
Advertisement
AdSense · Rectangle 336×280
More in this industry